SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) initially emerged in December 2019 in Wuhan, People's Republic of China, and its rapid spread led to a global pandemic. Vaccines are the single, most effective method of stopping the pandemic and concerns about vaccine safety have necessitated updates to the knowledge, especially in terms of allergic diseases. Patients with mastocytosis, who frequently experience recurrent anaphylaxis, constitute an important group that needs to be investigated as to whether the COVID-19 vaccines can be administered safely.